Table 1. Estimates of parameters for the integrated dose-biomarker-response model.
| Parameter | Definition | Estimates | RSE (%)1 | IIV (CV%)2 |
|---|---|---|---|---|
| Kin (U·mL−1·d−1) | TrxR production rate | 8.27 | 42.4 | 12.4 |
| Base (U/mL) | Initial TrxR activity | 39.7 | 8.60 | 9.6 |
| γ1 (d/mm) | Linear correction factor | 0.021 | 16.5 | NE3 |
| γ2 (−) | Hill's coefficient | 2.29 | 17.3 | NE |
| Smax (−) | Maximal TrxR inhibition | 5.95 | 31.9 | NE |
| SC50 (mg/kg) | Dose of ethaselen causing one-half maximal TrxR inhibition | 136 | 25.2 | NE |
| λ0 (d−1) | Exponential growth rate | 0.704 | 31.4 | NE |
| λ1 (mm3/d) | Linear growth rate | 321 | 11.5 | 32.7 |
| W (mm3) | Initial tumor volume | 103 | 3.9 | 14.2 |
| Emax (mm3/d) | Maximal tumor eradication effects | 130 | 4.8 | NE |
| EC50 (−) | Ratio of TrxR inhibition P causing one-half maximal tumor eradication effects | 0.0676 | 23.1 | 19.3 |
| Errpro | Proportional error | 20.22% | 13.6 | |
| Erradd (mm3) | Additive error | 141 | 78 |
1 Percentage relative standard error.
2 Percentage coefficient of inter-individual variability of the estimate.
3 Inter-individual variability was fixed to zero when CV<0.1%.